New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:35 EDTADXSAdvaxis receives notice of allowance for 2 patent applications
Advaxis has received notice of allowance from the U.S. Patent and Trademark Office on two patents covering the composition and methods of use for ADXS-cHER2. Advaxis is developing ADXS-cHER2 to target the Her2 receptor, which is overexpressed in certain solid-tumor cancers, including bone cancer, breast cancer, esophageal, and gastric cancer. Advaxis plans to initiate a Phase 1 trial with ADXS-cHER2 in pediatric osteosarcoma, for which it received Orphan Drug Designation, and is pursuing early development clinical collaborations for breast, esophageal and gastric cancers.
News For ADXS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 23, 2014
10:01 EDTADXSOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:06 EDTADXSAdvaxis initiated with a Buy at H.C. Wainwright
Subscribe for More Information
October 20, 2014
07:34 EDTADXSAdvaxis names Mauro Chief Medical Officer
Advaxis (ADXS) announced that it has appointed David Mauro, as executive vice president, Chief Medical Officer Mauro most recently served as executive director, section head oncology clinical development at Merck (MRK). In connection with his appointment, Mauro received a one-time inducement award of 165K restricted shares, of which 55K are fully vested and as of the grant date. The remaining shares vest annually over a two-year period.
October 15, 2014
07:36 EDTADXSAdvaxis provides clinical update for Phase 1/2 trial of ADXS-HPV candidate
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use